Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 59.7%

Neg 59.7% Neu 0% Pos 0%

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $50 to $45.

Comments

No comments yet. Be the first!